

Supervivencia general (OS) y cociente de riesgo (HR) en base al nivel de PD-L1 en NSCLC

KEYNOTE-189

Measurement	Regimen	
	Pembrolizumab + Chemotherapy	vs. Placebo + Chemotherapy
PD-L1 Status: <1%		
% OS at 12 Months:	61.0%	52.0%
HR:	HR (risk of death) = 0.59 (95% CI, 0.38-0.92)	
PD-L1 Status: 1-49%		
% OS at 12 Months:	71.5%	50.9%
HR:	HR (risk of death) = 0.55 (95% CI, 0.34-0.90)	
PD-L1 Status: >50%		
% OS at 12 Months:	73.0%	48.1%
HR:	HR (risk of death) = 0.42 (95% CI, 0.26-0.68)	